In:
International Journal of Cancer, Wiley, Vol. 141, No. 7 ( 2017-10), p. 1445-1457
Kurzfassung:
What's new? Cancer immunotherapy through antigen selection is difficult to apply in poorly immunogenic tumors. Genetic modification of tumor cells with anti‐CD3 antibody has been proposed as an alternative therapeutic strategy. Transgene delivery, however, remains a challenge in vivo . Here, the authors genetically modified hepatocellular carcinoma (HCC) cells with a constructed membrane‐bound anti‐CD3scfv gene within the tumor site using the E1A‐engineered human umbilical cord mesenchymal stem cells (HUMSC.E1A) transgene system. They found that membrane‐bound anti‐CD3scfv activated lymphocytes, which lysed HCC cells bypassing the expression of antigens or MHC restriction. The findings highlight the approach as a promising strategy for solid tumor immunotherapy.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
218257-9
ZDB Id:
1474822-8